Clinical Trials
282
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (260 trials with phase data)• Click on a phase to view related trials
CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults
- Conditions
- Rotavirus Infections
- Interventions
- Biological: 3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)Biological: 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)Other: Placebo
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 50
- Registration Number
- NCT06962904
- Locations
- 🇺🇸
Emory Children's Center - Vaccine Research Clinic, Atlanta, Georgia, United States
Efficacy of Flow Restrictors in Limiting Access of Liquid Medicines by Young Children
- Conditions
- Enhanced Child-safety Packaging
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 120
- Registration Number
- NCT06938620
CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults
- Conditions
- Rotavirus Infections
- Interventions
- Biological: 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)Biological: 3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)Other: Placebo
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 50
- Registration Number
- NCT06485258
- Locations
- 🇺🇸
Emory Children's Center - Vaccine Research Clinic, Atlanta, Georgia, United States
Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia
- Conditions
- MalariaPlasmodium FalciparumUncomplicated Malaria
- Interventions
- Drug: Amodiaquine-artesunate (ASAQ)Drug: Artemether+Lumefantrine (AL)
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 352
- Registration Number
- NCT06300970
- Locations
- 🇱🇷
Sinje Health Center, Garwula District, Sinje, Grand Cape Mount County, Sinje, Grand Cape Mount County, Liberia
🇱🇷Saclepea-Mahn Comprehensive Health Center Saclepea-Mahn District, Nimba County, Saclepea, Nimba County, Liberia
Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP
- Conditions
- Influenza
- Interventions
- Biological: FluQuadri
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 192
- Registration Number
- NCT06054269
- Locations
- 🇵🇪
Hospital Nacional Arzobispo Loayza, Lima, Peru
🇵🇪Hospital Nacional Cayetano Heredia, Lima, Peru
- Prev
- 1
- 2
- 3
- 4
- 5
- 56
- Next
News
Updated COVID-19 Vaccines Show Strong Protection Against Severe Illness in Comprehensive CDC Study
A comprehensive CDC VISION Network study spanning over 345,000 emergency department encounters and 111,000 hospitalizations found that 2023-2024 COVID-19 vaccines reduced critical illness risk by 48% during the first seven to 299 days after vaccination.
Rutgers Study Challenges FDA Heart Safety Warning for Epilepsy Drug Lamotrigine
Rutgers Health researchers found lamotrigine safe in older adults with epilepsy, contradicting a 2020 FDA safety warning about potential heart risks.
Trump Administration Halts Major HIV Vaccine Research Programs Despite Scientific Progress
The Trump administration has terminated funding for multiple HIV vaccine research programs, including major efforts at Duke Human Vaccine Institute and Scripps Research Institute that have been running since 2012.
MAHA Commission Proposes Comprehensive Pediatric Drug Safety Research Initiative
The MAHA Commission has outlined an enhanced research framework focused on drug safety in pediatric populations, addressing critical gaps in current safety monitoring systems.
FDA Overhauls COVID-19 Vaccine Approval Process, Limiting Access for Healthy Adults and Children
The FDA has announced major changes to COVID-19 vaccine approvals, requiring placebo-controlled clinical trials for shots intended for healthy adults and children, effectively ending routine annual approvals for these groups.
UIC Researchers Develop Groundbreaking Antibiotic Against Superbugs as Illinois Faces Rising Antimicrobial Resistance
University of Illinois Chicago researchers have developed a novel antibiotic that could make it 100 million times harder for bacteria to develop resistance, potentially revolutionizing treatment of drug-resistant infections.
EMA Suspends Valneva's IXCHIQ Chikungunya Vaccine for Elderly Following Safety Concerns
European Medicines Agency has suspended the use of Valneva's IXCHIQ chikungunya vaccine in people over 65 years old following reports of 17 serious adverse events, including two deaths, in elderly patients.
Home Administration of Long-Acting HIV Injectable Therapy Proves Safe and Effective as Clinic Treatment
A study by the Medical University of South Carolina demonstrates that home administration of long-acting injectable antiretroviral therapy (ART) for HIV patients is as safe and effective as clinic-based administration.
Pneumonia Antibiotic Piperacillin Shows Promise as Targeted Lyme Disease Treatment at 100-Fold Lower Doses
Northwestern University researchers screened nearly 500 FDA-approved compounds and identified piperacillin as a potentially more effective Lyme disease treatment than current standard doxycycline therapy.
U.S. Measles Outbreak Reaches 800 Cases, Marking Largest Since Disease Elimination in 2000
The United States is experiencing its largest measles outbreak since the disease was declared eliminated in 2000, with at least 800 confirmed cases nationwide and likely more unreported.